Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta‑analysis

Gan,Jiadi; Wang,Yingjin; Zhou,Xiaodong

doi:10.3892/etm.2018.6769

Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta‑analysis

Authors:
- Jiadi Gan
- Yingjin Wang
- Xiaodong Zhou
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: September 19, 2018 https://doi.org/10.3892/etm.2018.6769
Pages: 4479-4492
Copyright: © Gan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The efficacy of stem cell (SC) transplantation in patients with type 1 diabetes mellitus (T1DM) has remained to be fully elucidated. In the present study, a systematic review and meta‑analysis was performed to determine the clinical outcomes. Electronic databases, including PubMed, MEDLINE, WanFang and the Cochrane Library were screened for relevant studies published until January 13, 2018. The references of retrieved papers, systematic reviews and trial registries were manually screened for additional papers. Two authors were involved in screening the titles in order to select eligible studies, extract data and assess the risk of bias. Studies were pooled using a random‑effects model as well as the Begg's funnel plot and subgroup analysis was performed using Stata 14.0 software. A total of 47 studies were retrieved for detailed evaluation, of which 22 met the inclusion criteria. No substantial publication bias was identified. The meta‑analysis revealed that SC therapy increased C‑peptide levels when compared with placebo treatment in randomized‑controlled trials [RCT; standardized mean difference (SMD), 0.93; 95% confidence interval (CI) 0.23‑1.63] and self‑controlled trials (SMD, 0.66; 95% CI, ‑0.22 to 1.54). An analysis demonstrated that SC therapy was more efficient at reducing the glycated hemoglobin level compared with the control group in RCTs (SMD, 0.56; 95% CI; 0.06‑1.06; and SMD, 1.63; 95% CI, 0.92‑2.34, respectively). The graphs demonstrated that SC transplantation resulted in a reduction of insulin requirement. Furthermore, subgroup analyses revealed that patient age, medical history and the SC injection dose may be sources of the heterogeneity observed. The greatest benefit of SC transplantation was seen in patients aged ≥18 years or a medical history of <3 months. In addition, the SC injection dose of ≥107 IU/kg/day was more effective than <107 IU/kg/day when the cellular composition included mesenchymal SCs and hematopoietic SCs. In conclusion, SC therapy represents an efficient option for patients with T1DM. This systematic review was registered at the International prospective register of systematic reviews (no. 42018093930).

View Figures

View References

1	Shaw JE, Sicree RA and Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
2	Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ and Naghavi M: Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet. 378:1461–1484. 2011. View Article : Google Scholar : PubMed/NCBI
3	Garofalo C, Iazzetta N, Camocardi A, Pacilio M, Iodice C, Minutolo R, De Nicola L and Conte G: Anti-diabetics and chronic kidney disease. G Ital Nefrol. 32:pii2015.
4	Gholamhossein Y, Behrouz H and Asghar Z: Diabetic retinopathy risk factors: Plasma erythropoietin as a risk factor for proliferative diabetic retinopathy. Korean J Ophthalmol. 28:373–378. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bluestone JA, Herold K and Eisenbarth G: Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 464:1293–1300. 2010. View Article : Google Scholar : PubMed/NCBI
6	Cook JJ, Hudson I, Harrison LC, Dean B, Colman PG, Werther GA, Warne GL and Court JM: Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes. 38:779–783. 1989. View Article : Google Scholar : PubMed/NCBI
7	Ludvigsson J, Carlsson A, Deli A, Forsander G, Ivarsson SA, Kockum I, Lindblad B, Marcus C, Lernmark Å and Samuelsson U: Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. Diabetes Res Clin Pract. 100:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
8	Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, et al: Rituximab, B-lymphocyte depletion and preservation of beta-cell function. N Engl J Med. 361:2143–2152. 2009. View Article : Google Scholar : PubMed/NCBI
9	Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, et al: Teplizumab preserves C-peptide in recent-onset type 1 diabetes: Two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 62:3901–3908. 2013. View Article : Google Scholar : PubMed/NCBI
10	Luo X, Herold KC and Miller SD: Immunotherapy of type 1 diabetes: Where are we at and where should we be going. Immunity. 32:488–499. 2010. View Article : Google Scholar : PubMed/NCBI
11	Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, et al: Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 10:1870–1880. 2010. View Article : Google Scholar : PubMed/NCBI
12	Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM and Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 343:230–238. 2000. View Article : Google Scholar : PubMed/NCBI
13	McCall M and Shapiro AM: Update on islet transplantation. Cold Spring Harb Perspect Med. 2:a0078232012. View Article : Google Scholar : PubMed/NCBI
14	Jeong JH, Yook S, Hwang JW, Jung MJ, Moon HT, Lee DY and Byun Y: Synergistic effect of surface modification with Poly(ethylene glycol) and immunosuppressants on repetitive pancreatic islet transplantation into antecedently sensitized rat. Transplant Proc. 45:585–590. 2013. View Article : Google Scholar : PubMed/NCBI
15	Evgenov NV, Medarova Z, Pratt J, Pantazopoulos P, Leyting S, Bonner-Weir S and Moore A: In vivo imaging of immune rejection in transplanted pancreatic islets. Diabetes. 55:2419–2428. 2006. View Article : Google Scholar : PubMed/NCBI
16	Stegall MD, Lafferty KJ, Kam I and Gill RG: Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation. 61:1272–1274. 1996. View Article : Google Scholar : PubMed/NCBI
17	Newman RG, Ross DB, Barreras H, Herretes S, Podack ER, Komanduri KV, Perez VL and Levy RB: The allure and peril of hematopoietic stem cell transplantation: Overcoming immune challenges to improve success. Immunol Res. 57:125–139. 2013. View Article : Google Scholar : PubMed/NCBI
18	Chhabra P and Brayman KL: Stem cell therapy to cure type 1 diabetes: From hype to hope. Stem Cells Transl Med. 2:328–336. 2013. View Article : Google Scholar : PubMed/NCBI
19	Qi X, Guo X and Su C: Clinical outcomes of the transplantation of stem cells from various human tissue sources in the management of liver cirrhosis: A systematic review and meta-analysis. Curr Stem Cell Res Ther. 10:166–180. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kim G, Eom YW, Baik SK, Shin Y, Lim YL, Kim MY, Kwon SO and Chang SJ: Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases: Systematic review and Meta-analysis. J Korean Med Sci. 30:1405–1415. 2015. View Article : Google Scholar : PubMed/NCBI
21	Dave M, Mehta K, Luther J, Baruah A, Dietz AB and Faubion WA Jr: Mesenchymal stem cell therapy for inflammatory bowel disease: A systematic review and Meta-analysis. Inflamm Bowel Dis. 21:2696–2707. 2015. View Article : Google Scholar : PubMed/NCBI
22	Jeong H, Yim HW, Park HJ, Cho Y, Hong H, Kim NJ and Oh IH: Mesenchymal stem cell therapy for ischemic heart disease: Systematic review and Meta-analysis. Int J Stem Cells. 11:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
23	Hoekstra JB, van Rijn HJ, Erkelens DW and Thijssen JH: C-peptide. Diabetes Care. 5:438–446. 1982. View Article : Google Scholar : PubMed/NCBI
24	Gomez-Perez FJ, Aguilar-Salinas CA, Almeda-Valdes P, Cuevas-Ramos D, Lerman Garber I and Rull JA: HbA1c for the diagnosis of diabetes mellitus in a developing country. A position article. Arch Med Res. 41:302–308. 2010. View Article : Google Scholar : PubMed/NCBI
25	Preedy VR and Watson RR: Fasting Plasma Glucose. Springer; New York: 25. 2010
26	Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group, . Preferred reporting items for systematic reviews and Meta-analyses: The PRISMA statement. Ann Intern Med. 151:264–269, W64. 2009. View Article : Google Scholar : PubMed/NCBI
27	Higgins J and Green S: Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. naunyn-schmiedebergs archiv für experimentelle pathologie und pharmakologie. 5 Suppl:S382014.
28	Anderson ML and Peterson ED: Compliance with results reporting at ClinicalTrials.gov. N Engl J Med. 372:2370–2371. 2015. View Article : Google Scholar : PubMed/NCBI
29	Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
30	Higgins JPT and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002. View Article : Google Scholar : PubMed/NCBI
31	Deeks JJ, Altman DG and Bradburn MJ: Statistical methods for examining heterogeneity and combining results from several studies in Meta-analysis. Systematic Reviews in Health Care Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd. Wiley-Blackwell; Chichester: 2008
32	Sterne JA, Gavaghan D and Egger M: Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol. 53:1119–1129. 2000. View Article : Google Scholar : PubMed/NCBI
33	Ye L, Li L, Wan B, Yang M, Hong J, Gu W, Wang W and Ning G: Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus. Stem Cell Res Ther. 8:902017. View Article : Google Scholar : PubMed/NCBI
34	Thakkar UG, Trivedi HL, Vanikar AV and Dave SD: Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy. 17:940–947. 2015. View Article : Google Scholar : PubMed/NCBI
35	Snarski E, Milczarczyk A, Hałaburda K, Torosian T, Paluszewska M, Urbanowska E, Król M, Boguradzki P, Jedynasty K, Franek E and Wiktor-Jedrzejczak W: Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: Long-term observations. Bone Marrow Transplant. 51:398–402. 2016. View Article : Google Scholar : PubMed/NCBI
36	Delgado E, Perez-Basterrechea M, Suarez-Alvarez B, Zhou H, Revuelta EM, Garcia-Gala JM, Perez S, Alvarez-Viejo M, Menendez E, Lopez-Larrea C, et al: Modulation of autoimmune T-cell memory by stem cell educator therapy: Phase 1/2 clinical trial. EBiomedicine. 2:2024–2036. 2015. View Article : Google Scholar : PubMed/NCBI
37	Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, et al: Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: A pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 39:149–157. 2016. View Article : Google Scholar : PubMed/NCBI
38	Giannopoulou EZ, Puff R, Beyerlein A, von Luettichau I, Boerschmann H, Schatz D, Atkinson M, Haller MJ, Egger D, Burdach S and Ziegler AG: Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: A non-randomized, controlled trial. Pediatr Diabetes. 15:100–109. 2014. View Article : Google Scholar : PubMed/NCBI
39	D'Addio F, Valderrama Vasquez A, Ben Nasr M, Franek E, Zhu D, Li L, Ning G, Snarski E and Fiorina P: Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: A multicenter analysis. Diabetes. 63:3041–3046. 2014. View Article : Google Scholar : PubMed/NCBI
40	Carlsson PO, Schwarcz E, Korsgren O and Le Blanc K: Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 64:587–592. 2015. View Article : Google Scholar : PubMed/NCBI
41	Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S and Wang Y: Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endoc J. 60:347–357. 2013. View Article : Google Scholar
42	Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, et al: Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with type 1 diabetes. Biol Blood Marrow Transplant. 19:1126–1129. 2013. View Article : Google Scholar : PubMed/NCBI
43	Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, et al: Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. 10:32012. View Article : Google Scholar : PubMed/NCBI
44	Zhang X, Ye L, Hu J, Tang W, Liu R, Yang M, Hong J, Wang W, Ning G and Gu W: Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient. PLoS One. 7:e318872012. View Article : Google Scholar : PubMed/NCBI
45	Li L, Shen S, Ouyang J, Hu Y, Hu L, Cui W, Zhang N, Zhuge YZ, Chen B, Xu J and Zhu D: Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab. 97:1729–1736. 2012. View Article : Google Scholar : PubMed/NCBI
46	Gu W, Hu J, Wang W, Li L, Tang W, Sun S, Cui W, Ye L, Zhang Y, Hong J, et al: Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care. 35:1413–1419. 2012. View Article : Google Scholar : PubMed/NCBI
47	Yu W, Gao H, Yu X, Wang L, Yan S and Wang Y: Umbilical cord mesenchymal stem cells transplantation for newly-onset type 1 diabetes. J Clin Rehabil Tissue Engineering Res. 15:4363–4366. 2011.
48	Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Sumrall TM, Wingard JR, Theriaque DW, Shuster JJ, et al: Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care. 34:2567–2569. 2011. View Article : Google Scholar : PubMed/NCBI
49	Feng K, Xu YW, Ye FG, Xiao L, Ma XH, Gao Y, Zhang X, Yao SZ and Shi BY: Autologous peripheral blood hematopoietic stem cell transplantation in the treatment of type 1 diabetic mellitus: A report of 16 cases. Zhonghua Yi Xue Za Zhi. 91:1966–1969. 2011.(In Chinese). PubMed/NCBI
50	Vanikar AV, Dave SD, Thakkar UG and Trivedi HL: Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: A novel therapy for insulin-dependent diabetes mellitus. Stem Cells Int. 2010:5823822010. View Article : Google Scholar : PubMed/NCBI
51	Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Król M, Boguradzki P, Jedynasty K, Franek E and Wiktor-Jedrzejczak W: Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant. 46:562–566. 2011. View Article : Google Scholar : PubMed/NCBI
52	Gu WQ, Sun SY, Hu J, Tang W, Wei JS, Zhu LP, Hong J, Tang ZY, Liu JM, Li XY, Wang WQ, et al: Efficacy and safety of autologous hematopoietic stem cell transplantation in treating type 1 diabetes mellitus. Chin J Endocrinol Metabol. 53:1023–1026. 2010.(In Chinese).
53	Haller MJ, Wasserfall CH, Mcgrail KM, Cintron M, Brusko TM, Wingard JR, Kelly SS, Shuster JJ, Atkinson MA and Schatz DA: Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care. 32:2041–2046. 2009. View Article : Google Scholar : PubMed/NCBI
54	Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, et al: C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 301:1573–1579. 2009. View Article : Google Scholar : PubMed/NCBI
55	Wang S, Li Y, Zhao J, Zhang J and Huang Y: Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant. 19:538–546. 2013. View Article : Google Scholar : PubMed/NCBI
56	Yanai G, Hayashi T, Zhi Q, Yang KC, Shirouzu Y, Shimabukuro T, Hiura A, Inoue K and Sumi S: Electrofusion of mesenchymal stem cells and islet cells for diabetes therapy: A rat model. PLoS One. 8:e644992013. View Article : Google Scholar : PubMed/NCBI
57	Glycosylated hemoglobin assays in the management and diagnosis of diabetes mellitus. Health and Public Policy Committee, American College of Physicians. Ann Intern Med. 101:710–713. 1984. View Article : Google Scholar : PubMed/NCBI
58	Haller MJ, Viener H, Brusko T, Wasserfall C, Mcgrail K, Staba S, Cogle C, Atkinson M and Schatz DA: Insulin requirements, HbA1c and stimulated C-peptide following autologous umbilical cord blood transfusion in children with T1D. Diabetes. 56:A822007.